Facial Injectables Market Report by Product Type (Collagen, Hyaluronic Acid (HA), Botulinum Toxin Type A, Calcium Hydroxylapatite (CaHA), Polymethylmethacrylate Beads (PMMA Microspheres), Poly-L-Lactic Acid (PLLA), and Others), Application Type (Aesthetics, Therapeutics), Application (Facial Line Correction, Lip Augmentation, Face Lift, Acne Scar Treatment, and Others), End User (Hospitals, Dermatology Clinics, and Others), and Region 2023-2028
The global facial injectables market size reached US$ 7.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 13.3 Billion by 2028, exhibiting a growth rate (CAGR) of 9.64% during 2023-2028.
Facial injectables are administered on specific areas of the face to enhance the physical appearance of the skin. These injectables are generally made using collagen, hyaluronic acid and calcium hydroxylapatite that help restore the elasticity of the skin. They are used to reduce wrinkles, augment lips, enhance shallow contours and raise depressed scars. Currently, facial injectables are gaining traction worldwide as they are safe, cost-effective and require minimal downtime.
As collagen production and formation of fat under the skin decline with age, the skin becomes more susceptible to wrinkles and sagging. This, in confluence with the growing geriatric population and the desire to retain a young and healthy skin, represents one of the key factors bolstering the market growth. Apart from this, the escalating demand for minimally invasive surgeries, coupled with the rising trend of medical and cosmetic tourism, is contributing to the market growth. Moreover, as excessive sun exposure leads to tissue breakdown of the skin, the demand for facial injectables is escalating among outgoing individuals. Furthermore, inflating disposable incomes, the rising influence of social media, and the growing number of professional practitioners and users willing to try organic and biodegradable materials are some of the other factors influencing the market positively. Besides this, the key players are also offering customized facial injectables to provide a personalized experience to users, which, in turn, is anticipated to create a positive outlook for the market in the coming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global facial injectables market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, application type, application and end user.
Breakup by Product Type:
Hyaluronic Acid (HA)
Botulinum Toxin Type A
Calcium Hydroxylapatite (CaHA)
Polymethylmethacrylate Beads (PMMA Microspheres)
Poly-L-Lactic Acid (PLLA)
Breakup by Application Type:
Breakup by Application:
Facial Line Correction
Acne Scar Treatment
Breakup by End User:
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Allergan Plc, Anika Therapeutics Inc., Bloomage BioTechnology, Johnson & Johnson, Galderma Pharma S.A., Integra LifeSciences, Ipsen (Mayroy SA), Medytox Inc., Merz Holding GmbH & Co. KG, Prollenium Medical Technologies Inc., Sanofi, SciVision Biotech Inc., Sinclair Pharma (Huadong Medicine Co. Ltd.), Suneva Medical Inc. and Bausch Health Companies Inc.
Base Year of the Analysis
Product Type, Application Type, Application, End User, Region
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Allergan Plc, Anika Therapeutics Inc., Bloomage BioTechnology, Johnson & Johnson, Galderma Pharma S.A., Integra LifeSciences, Ipsen (Mayroy SA), Medytox Inc., Merz Holding GmbH & Co. KG, Prollenium Medical Technologies Inc., Sanofi, SciVision Biotech Inc., Sinclair Pharma (Huadong Medicine Co. Ltd.), Suneva Medical Inc. and Bausch Health Companies Inc.
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
According to the estimates by IMARC Group, the global facial injectables market is expected to witness a CAGR of 9.64% from 2023-2028.
The expanding cosmetic surgery sector with the rising consumer consciousness towards physical appearances represents one of the key drivers for the global facial injectables market.
The emergence of minimally- or non-invasive cosmetic surgeries along with the increasing demand for organic and biodegradable product variants account for some of the key industry trends in the global facial injectables market.
Sudden outbreak of the COVID-19 pandemic had led to the cancellation or postponement of several elective cosmetic surgeries to mitigate the risk of coronavirus infection upon clinic visits that had adversely impacted the market for facial injectables.
On the basis of the product type, the market has been bifurcated into collagen, Hyaluronic Acid (HA), Botulinum Toxin Type A, Calcium Hydroxylapatite (CaHA), Polymethylmethacrylate Beads (PMMA Microspheres), Poly-L-Lactic acid (PLLA), and others. Currently, Botulinum Toxin Type A holds the majority of the total market share.
Based on the application type, the market has been segmented into aesthetics and therapeutics. Amongst these, aesthetics represent the largest segment.
On the basis of the end user, the market has been bifurcated into hospitals, dermatology clinics, and others. Among these, hospitals hold the largest market share.
Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
The key companies in the global facial injectables market are Allergan Plc, Anika Therapeutics Inc., Bloomage BioTechnology, Johnson & Johnson, Galderma Pharma S.A., Integra LifeSciences, Ipsen (Mayroy SA), Medytox Inc., Merz Holding GmbH & Co. KG, Prollenium Medical Technologies Inc., Sanofi, SciVision Biotech Inc., Sinclair Pharma (Huadong Medicine Co. Ltd.), Suneva Medical Inc., and Bausch Health Companies Inc.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.